What does BLES stand for?

Food and Drug Administration (FDA) 510(k) clearance for the Intact (R) Excise XL - a larger version of the Company's already FDA approved wands, used with the Intact (R) Breast Lesion Excision System (BLES).

The bladed tip Intact Advance wand makes the Intact(R) Breast Lesion Excision System (BLES) more intuitive to users familiar with vacuum-assisted core needle biopsy devices.

June 26 /PRNewswire/ -- Researchers today will begin a large, multi-center, multi-disciplinary clinical study designed to determine whether women at high risk of developing breast cancer can avoid an open surgical biopsy by demonstrating that a definitive diagnosis can be made from a tissue sample collected with the minimally-invasive Intact(TM) Breast Lesion Excision System (BLES).

16 /PRNewswire/ -- Intact Medical Corporation (formerly Neothermia Corporation), an emerging leader in minimally invasive systems for the diagnosis of breast cancer, today announced the establishment of a Scientific Advisory Board focused chiefly on issues related to the field of breast cancer detection and the ongoing development of the Company's FDA-cleared Intact (TM) Breast Lesion Excision System.

Concurrent with the name change, the Company has also re-named its FDA-approved breast biopsy system the Intact(TM) Breast Lesion Excision System -- previously known as the en-bloc(TM) Biopsy System.